<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	
	>
<channel>
	<title>
	Comments on: Kite and Humanigen Announce Clinical Collaboration to Evaluate Investigational Combination of Yescarta® (Axicabtagene Ciloleucel) with Lenzilumab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma	</title>
	<atom:link href="https://www.novumpr.nl/2019/05/31/kite-and-humanigen-announce-clinical-collaboration-to-evaluate-investigational-combination-of-yescarta-axicabtagene-ciloleucel-with-lenzilumab-in-relapsed-refractory-diffuse-large-b-cell-lymph/feed/" rel="self" type="application/rss+xml" />
	<link>https://www.novumpr.nl/2019/05/31/kite-and-humanigen-announce-clinical-collaboration-to-evaluate-investigational-combination-of-yescarta-axicabtagene-ciloleucel-with-lenzilumab-in-relapsed-refractory-diffuse-large-b-cell-lymph/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=kite-and-humanigen-announce-clinical-collaboration-to-evaluate-investigational-combination-of-yescarta-axicabtagene-ciloleucel-with-lenzilumab-in-relapsed-refractory-diffuse-large-b-cell-lymph</link>
	<description>NovumPR press releases</description>
	<lastBuildDate>Fri, 31 May 2019 12:46:39 +0000</lastBuildDate>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.8.3</generator>
</channel>
</rss>
